Jazz Pharma investing $100 million in UK manufacturing

Ireland-headquartered Jazz Pharmaceuticals (Nasdaq: JAZZ) and its subsidiary GW Pharmaceuticals – a UK-based world leader in discovering, developing and delivering regulatory approved cannabis-based medicines – today announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne. Jazz acquired GW last year for around $7.2 billion.

The new state-of-the-art facility will be around 60,000 sq. ft, with an investment of over $100 million (~£75 million). Once operational, the facility will create more than 100 highly skilled new jobs. Due to open in 2024, the facility is designed to support the company’s two regulatory-approved cannabis-based medicines and support future capacity for new medicines under development. Jazz currently manufactures the extract, active pharmaceutical ingredients and the formulated drug products at KSP, occupying 12 buildings with more than 400 employees, making it, and the UK, the heart of our global cannabinoid manufacturing operations.

Continued commitment to the UK